Study guide
3.2 Chronic Coronary Disease & Antiplatelet Strategies
Board Certified Ambulatory Care Pharmacist BCACP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Patient Care Process
1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence
2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia
2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons
3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation
3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
4 Chapter 4: Endocrine & Metabolic Disorders
4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing
5 Chapter 5: Respiratory Care & Pulmonology
5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling
6 Chapter 6: Renal, Urological & Reproductive Health
6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity
7 Chapter 7: Neuropsychiatry & Behavioral Health
7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders
8 Chapter 8: Pain Management & Rheumatology
8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy
9 Chapter 9: Infectious Diseases & Immunizations
9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations
10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety
10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety
11 Chapter 11: Biostatistics, Study Design & Literature Evaluation
11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics
12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery
12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest
3.2 Chronic Coronary Disease & Antiplatelet Strategies
Key Takeaways Explain This Topic AI
First-line antianginal therapy for chronic coronary disease (CCD) consists of beta-blockers titrated to a resting heart rate of 55 to 60 bpm; dihydropyridine calcium channel blockers or long-acting nitrates serve as first-line add-on agents when angina persists.
Ranolazine selectively inhibits the late inward sodium current (INa), reducing diastolic myocardial wall tension without lowering blood pressure or heart rate, making it ideal for patients with baseline bradycardia or hypotension.
Standard dual antiplatelet therapy (DAPT) duration post-percutaneous coronary intervention (PCI) is 12 months for acute coronary syndromes (ACS) and 6 months for elective stenting in chronic coronary disease; high bleeding risk (HBR) warrants shortening to 1 to 3 months.
In patients with atrial fibrillation undergoing PCI, the guideline-recommended antithrombotic strategy is double therapy with a direct oral anticoagulant (DOAC) and clopidogrel 75 mg daily; aspirin is discontinued at hospital discharge (or up to 1-4 weeks) to minimize major bleeding.
Prasugrel is strictly contraindicated in patients with a history of stroke or transient ischemic attack (TIA) due to significantly increased intracranial hemorrhage risk, while ticagrelor requires low-dose aspirin (≤100 mg daily) and is associated with self-limiting dyspnea.
Last updated: September 2026
3.2 Chronic Coronary Disease & Antiplatelet Strategies
BCACP Exam Anchor: Ambulatory care pharmacists must excel in tailoring antianginal pharmacotherapy based on patient hemodynamics (heart rate, blood pressure, and ventricular function) while navigating complex antiplatelet regimens. Critical exam targets include P2Y12 inhibitor contraindications (e.g., prasugrel black box warnings), CYP2C19 drug interactions, DAPT duration algorithms, and the definitive transition to "double therapy" (DOAC + clopidogrel) in patients with atrial fibrillation undergoing PCI.
Chronic Coronary Disease: Pathophysiology & Management Principles
Chronic coronary disease (CCD)—formerly termed stable ischemic heart disease (SIHD)—results from an imbalance between myocardial oxygen supply and myocardial oxygen demand : Myocardial Oxygen Demand ∝ Heart Rate × Contractility × Left Ventricular Wall Tension (Afterload/Preload) \text{Myocardial Oxygen Demand} \propto \text{Heart Rate} \times \text{Contractility} \times \text{Left Ventricular Wall Tension (Afterload/Preload)} Myocardial Oxygen Demand ∝ Heart Rate × Contractility × Left Ventricular Wall Tension (Afterload/Preload)
Foundational Secondary Prevention Regimen
Every patient with documented CCD must receive comprehensive secondary prevention to reduce major adverse cardiovascular events (MACE):
Antiplatelet Therapy: Aspirin 81 mg daily indefinitely (or clopidogrel 75 mg daily if aspirin-allergic).
High-Intensity Statin: Atorvastatin 80 mg daily or Rosuvastatin 20–40 mg daily to achieve ≥ 50 % \ge 50\% ≥ 50% LDL-C reduction and a target LDL-C < 55 to 70 mg/dL \text{LDL-C} < 55\text{ to } 70\text{ mg/dL} LDL-C < 55 to 70 mg/dL . Add ezetimibe or PCSK9 inhibitors if LDL targets remain unmet.
Blood Pressure Control: Target BP < 130 / 80 mmHg \text{BP} < 130/80\text{ mmHg} BP < 130/80 mmHg utilizing ACE inhibitors or ARBs, particularly if concomitant diabetes, CKD, or HFrEF is present.
Cardiovascular-Protective Diabetes Agents: Prioritize SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiovascular event reduction.
Stepwise Antianginal Pharmacotherapy
Antianginal medications alleviate exertional symptoms and improve exercise tolerance by reducing myocardial oxygen demand or enhancing coronary perfusion. They are sequenced according to patient-specific hemodynamics.
Antianginal Class First-Line & Preferred Agents Mechanism of Action Hemodynamic Impact & Target Clinical Nuances & Contraindications
Beta-Blockers (First-Line Standard) Metoprolol succinate , Atenolol , Bisoprolol , Carvedilol Negative chronotrope and inotrope; decreases wall tension; prolongs diastole to enhance coronary filling Target resting HR: 55–60 bpm ; Exertional HR: ≤ 100 bpm \le 100\text{ bpm} ≤ 100 bpm Preferred first-line in all CCD patients, especially post-MI or with HFrEF. Avoid abrupt cessation (rebound tachycardia/ischemia). Caution in severe sinus bradycardia, high-degree AV block, and severe active reactive airway disease.
Dihydropyridine CCBs (First-Line Add-on or BB Alternative) Amlodipine (2.5–10 mg QD); Felodipine (2.5–10 mg QD) Potent peripheral and coronary arteriolar vasodilation; decreases afterload Lowers BP ; No direct effect on SA/AV nodes (no bradycardia) Drug of choice to combine with beta-blockers when angina persists. Excellent in Prinzmetal (vasospastic) angina. Side effect: Dose-dependent peripheral pedal edema (precapillary dilation).
Non-Dihydropyridine CCBs (BB Alternative Monotherapy) Diltiazem ER (120–360 mg QD); Verapamil SR (120–480 mg QD) Inhibits L-type calcium channels in SA/AV nodal and myocardial tissue; slows conduction and lowers inotropy Lowers HR and BP Alternative to beta-blockers if BBs are contraindicated or poorly tolerated. Contraindication: Do NOT combine non-DHP CCBs with beta-blockers (risk of severe bradycardia and complete heart block). Contraindicated in HFrEF (LVEF ≤40%). Constipation prominent with verapamil.
Long-Acting Nitrates (Add-on for Refractory Angina) Isosorbide mononitrate (ISMN) (Imdur 30–120 mg QD) ; Isosorbide dinitrate (ISDN) (10–40 mg TID) Converted to nitric oxide; causes systemic venodilation (reduces preload/wall stress) and epicardial coronary vasodilation Reduces preload ; May cause reflex tachycardia Requires a 10 to 14-hour nitrate-free interval daily to prevent nitrate tolerance. Co-administration with PDE-5 inhibitors is absolutely contraindicated (severe hypotension/death).
Ranolazine (Ranexa) (Metabolic Antianginal) Ranolazine (500–1000 mg PO BID) Selectively inhibits late inward sodium current ( I Na I_{\text{Na}} I Na ); reduces intracellular sodium and calcium overload; decreases diastolic wall tension Zero effect on HR or BP (Neutral hemodynamics) Ideal for patients with baseline bradycardia, hypotension, or who remain symptomatic on BB + CCB. Dose-dependent QTc prolongation . Max dose 500 mg BID with moderate CYP3A4 inhibitors (diltiazem, verapamil). Contraindicated in hepatic cirrhosis.
Sublingual Nitroglycerin Patient Counseling
All CCD patients must be prescribed sublingual nitroglycerin (SL NTG 0.4 mg) for acute angina management:
Action Plan at Symptom Onset: Sit down immediately (prevents orthostatic syncope). Place 1 tablet under the tongue and allow it to dissolve; do not swallow or chew.
EMS Activation Rule: If chest pain is unimproved or worsening after 5 minutes , call 911 immediately . While awaiting EMS, take a second dose 5 minutes after the first, and a third dose 5 minutes later (maximum of 3 doses in 15 minutes).
Storage & Stability: Keep tablets in the original amber glass container with the metal cap tightly closed. Protect from heat, moisture, and light. Do not store in pill organizers or carry in pockets close to body heat. Replace opened bottles every 6 months .
PDE-5 Inhibitor Interaction: Absolute contraindication: Do not take SL NTG within 24 hours of sildenafil or vardenafil , or within 48 hours of tadalafil .
Oral Antiplatelet Agents: Comparative Pharmacology
Dual antiplatelet therapy (DAPT) combining aspirin with an oral P2Y 12 \text{P2Y}_{12} P2Y 12 receptor antagonist is the cornerstone of post-PCI and acute coronary syndrome care.
- Drug / Property Clopidogrel (Plavix) Prasugrel (Effient) Ticagrelor (Brilinta)
- Chemical Class Thienopyridine Thienopyridine Cyclopentyltriazolopyrimidine (CPTP)
Mechanism & Binding Irreversible P2Y 12 \text{P2Y}_{12} P2Y 12 antagonist Irreversible P2Y 12 \text{P2Y}_{12} P2Y 12 antagonist Reversible allosteric P2Y 12 \text{P2Y}_{12} P2Y 12 antagonist
Metabolic Activation Prodrug: Requires 2-step hepatic CYP activation (principally CYP2C19 ) Prodrug: 1-step activation by intestinal esterases and CYP3A4/CYP2B6 Active drug : No metabolic activation required (rapid onset/offset)
Standard Dosing Loading: 300–600 mg PO; Maintenance: 75 mg PO QD Loading: 60 mg PO; Maintenance: 10 mg PO QD ; (5 mg QD if weight <60 kg or age ≥75) Loading: 180 mg PO; Maintenance: 90 mg PO BID ; (60 mg PO BID after 12 months DAPT)
Onset & Potency Moderate onset (2–4 hours); moderate platelet inhibition Rapid onset (30 min); potent platelet inhibition Rapid onset (30 min); potent platelet inhibition
Boxed Warnings & Absolute Contraindications Black Box Warning: Diminished antiplatelet effect in CYP2C19 poor metabolizers (*2, *3 loss-of-function alleles). Black Box Warning: Fatal bleeding risk. Strictly contraindicated in patients with a prior history of TIA or Stroke! Black Box Warning: Fatal bleeding. High maintenance aspirin doses >100 mg daily decrease ticagrelor efficacy (maintain aspirin at 81 mg daily).
Unique Adverse Effects & Drug Interactions Avoid strong CYP2C19 inhibitors ( omeprazole , esomeprazole ); pantoprazole is the preferred PPI. High bleeding risk in patients ≥ 75 \ge 75 ≥ 75 years old (generally not recommended unless high ischemic risk). Dyspnea (~15%, mediated by adenosine reuptake inhibition; usually self-limiting), asymptomatic ventricular pauses , hyperuricemia/gout .
DAPT Durations: ACS vs. Chronic Coronary Disease
The optimal duration of DAPT balances ischemic protection (preventing stent thrombosis, recurrent MI) against the risk of major bleeding. Percutaneous Coronary Intervention (PCI)
- │
- ┌─────────────────────────────────┴─────────────────────────────────┐
- ▼ ▼
- Elective PCI for Chronic CAD ACS Presentation (STEMI/NSTEMI)
- │ │
- ┌───────────┴───────────┐ ┌───────────┴───────────┐
- ▼ ▼ ▼ ▼
- Standard Bleeding Risk High Bleeding Risk (HBR) Standard Bleeding Risk High Bleeding Risk (HBR)
- (PRECISE-DAPT <25) (PRECISE-DAPT ≥25 / ARC-HBR) (PRECISE-DAPT <25) (PRECISE-DAPT ≥25 / ARC-HBR)
- │ │ │ │
- 6 Months DAPT 1-3 Months DAPT 12 Months DAPT 1-6 Months DAPT
- (Aspirin + Clopidogrel) (Short DAPT → Monotherapy) (Aspirin + Ticagrelor/ (Short DAPT → P2Y12i Monotherapy
- │ Prasugrel) or Aspirin)
- ▼ │
- Lifelong Single Antiplatelet ▼
- (Aspirin 81 mg daily) Lifelong Single Antiplatelet
- (Aspirin 81 mg daily)
Standard ACS Post-PCI: 12 months of DAPT with aspirin 81 mg + potent P2Y 12 \text{P2Y}_{12} P2Y 12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel based on PLATO and TRITON-TIMI 38 trials).
Elective Stenting for Chronic CAD: 6 months of DAPT with aspirin 81 mg + clopidogrel 75 mg daily.
High Bleeding Risk (HBR) Customization: In patients with high bleeding risk (e.g., PRECISE-DAPT score ≥ 25 \ge 25 ≥ 25 , ARC-HBR criteria met, severe thrombocytopenia, recent bleeding):
ACS: Shorten DAPT to 1 to 6 months , followed by P2Y 12 \text{P2Y}_{12} P2Y 12 inhibitor monotherapy (ticagrelor or clopidogrel) or aspirin.
Chronic CAD: Shorten DAPT to 1 to 3 months , followed by single antiplatelet monotherapy.
Atrial Fibrillation + PCI: Double vs. Triple Therapy
When a patient with an indication for oral anticoagulation (e.g., atrial fibrillation with CHA 2 DS 2 -VASc ≥ 2 \text{CHA}_2\text{DS}_2\text{-VASc} \ge 2 CHA 2 DS 2 -VASc ≥ 2 in men or ≥ 3 \ge 3 ≥ 3 in women) undergoes PCI, combining full-dose anticoagulation with DAPT ("Triple Therapy") produces an unacceptable 3- to 4-fold increase in major bleeding.
Modern Consensus: Double Therapy as the Default Strategy
Landmark clinical trials (PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI) demonstrated that omitting aspirin upon hospital discharge dramatically reduces major bleeding by 40% to 50% with no statistically significant increase in stent thrombosis or ischemic stroke .
Default Regimen ("Double Therapy"): DOAC (at standard stroke-prevention dose) + Clopidogrel 75 mg daily .
Aspirin Duration: Aspirin 81 mg is administered during the acute PCI procedure and discontinued at hospital discharge (or continued for up to 1 to 4 weeks only in rare cases with extreme anatomical thrombotic risk and low bleeding risk).
P2Y 12 \text{P2Y}_{12} P2Y 12 Inhibitor Selection: Clopidogrel 75 mg daily is the mandatory P2Y 12 \text{P2Y}_{12} P2Y 12 inhibitor of choice . Prasugrel and ticagrelor are strictly avoided in double/triple therapy regimens due to unacceptably high rates of major hemorrhage.
Duration of Double Therapy: Clopidogrel is continued for 6 to 12 months post-PCI. After 6 to 12 months, the antiplatelet agent is permanently discontinued, and the patient continues lifelong DOAC monotherapy .